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Abstract
Background: Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure
viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and
its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve
HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether
the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a
virological response in heavily pre-treated HIV-infected patients.
Methods: Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study
(SHCS). We assessed patients’ virological success after their antiretroviral therapy was switched following resistance
testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the
association between the type of resistance test and virological response (HIV-1 RNA <50 copies/mL or ≥1.5log
reduction).
Results: Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis.
Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with >2
previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-
2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68,
95% CI 1.31-2.15).
Conclusions: In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a
higher rate of treatment success.
Background
Combination antiretroviral therapy (cART) has dramati-
cally reduced HIV related morbidity and mortality. Potent
new drugs for patients with multiple drug resistance have
been introduced [1-5]. Nevertheless, virological failure in
treatment-experienced patients is still a major concern
and therefore HIV drug resistance testing has a key role
for the optimal choice of active drugs in patients with
multiple drug failure. Accordingly, current guidelines
recommend resistance testing for patients with multiple
drug failure, but also for newly infected individuals and for
pregnant women as transmission of resistant HIV mutants
to therapy naïve individuals are a rising concern [6-9].
Two technical principles are in use today for resistance
testing: Genotypic resistance tests (GRT) and phenotypic
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resistance tests (PRT). GRT is based on population gene
sequencing of defined DNA segments, typically to detect
mutations, which represent at least 20% of the virus popu-
lation and confer HIV-1 drug resistance [10,11]. As a spe-
cial form of genotyping, virtual PRT (vPRT) correlates
genotypic data for plasma HIV-1 RNA of a candidate gene
with a large database of paired biological and clinical phe-
notypes [12-15]. Numerous genotypic interpretation sys-
tems have become available during the past decade, which
provide excellent prediction of drug response. On the
other hand, comparing different algorithms, some very sig-
nificant differences and opposite predictions continue to
be observed for the interpretation of the impact of muta-
tional patterns (T. Klimkait, manuscript in preparation).
PRT assesses viral expression. A special form of it, the
replicative phenotypic resistance test (rPRT) utilizes sev-
eral replication cycles of a recombinant infectious virus
to follow viral propagation in the presence of antiretro-
viral drugs [16,17]. By permitting several cycles of viral
replication in vitro rPRT can detect viral minorities
below one percent [18]. However, rPRT is more costly,
and takes longer than GRT.
Several studies have demonstrated the clinical benefit
and cost-effectiveness of GRT [19-25] compared to stan-
dard of care. This study was designed to analyse
whether the dissecting, sensitive format of PRT may
provide a diagnostic benefit over GRT. Analyses com-
paring virtual PRT to GRT have thus far not been able
to document a clear clinical advantage for PRT with a
higher proportion of patients achieving a suppressed
viral load [14,15,26-30]. Our first retrospective single
centre analysis of GRT combined with a highly sensitive
rPRT already suggested, although statistically underpow-
ered, that patients being switched to new cART based
on drug choice from a combination of both tests tended
to have better virological response than those with only
GRT-based resistance information [31].
In the present study we included all available data of
prospectively conducted resistance tests for patients
enrolled in the much larger multicentre Swiss HIV
Cohort Study (SHCS) and compared the virological out-
come in patients initiating a new antiretroviral drug regi-
men based on results of either GRT alone or rPRT
combined with GRT. The highly sensitive format of rPRT
used in the SHCS allows the detection of less than 1% of
resistant virus in a clinical sample with a mixed virus
population [18]. We therefore explored whether the com-
plementing information of rPRT improves patient out-
come when used routinely in the clinical setting.
Methods
Study population
The SHCS is a prospective cohort study with continuing
enrollment of HIV-infected individuals aged 16 years or
older [32]. The Swiss HIV cohort study has been
approved by ethical committees of all participating insti-
tutions. Written informed consent has been obtained
from all participating patients. Clinical visits take place
every six months at seven outpatient clinics of partici-
pating HIV-centres, associated hospitals, or specialized
private doctors’ offices. Any request for a resistance test
as well as information on indication and outcome of
current and previous therapies are recorded in the cen-
tral database of the SHCS. Individuals who had a pro-
spective resistance test performed between 2002 and
2006 for which the physician had access to results prior
to making clinical decisions were eligible for the study if
the following criteria were fulfilled; (i) cART was chan-
ged within one year after a resistance test was per-
formed, (ii) the patient was off treatment for <6 months
following the resistance test before starting a new regi-
men and (iii) at least one HIV-1 viral load measurement
was available following the switch of antiretroviral ther-
apy. Patients on any protocol for structured treatment
interruption studies were excluded. In situations where
multiple resistance testing was done only the first eligi-
ble test for an individual was utilized. Patients were fol-
lowed from the time of the switch to a new cART
regimen following resistance testing to the earliest of
any of the following events: switch to a new cART regi-
men due to virological failure, going off treatment,
death, loss to follow-up, or the closing date of the study,
July 31, 2008.
The reason for resistance testing has to be provided by
the clinician ordering a given resistance test. The speci-
fied categories for resistance testing are: drug naive
prior to initiation of first therapy, primary infection, sus-
picion for resistant virus transmission, pregnancy, and
drug failure. The indication “primary infection” is speci-
fied by characteristics of very early infection stages with
skin rash, very high virus load and incomplete immu-
noreactivity; “resistant virus transmission” is indicated
when high promiscuity or the involvement of highly
therapy-experienced individuals is suspected. When the
reason for testing was missing, we utilized information
from the SHCS to classify patients. Individuals were
considered to have had testing for drug failure if they
had either RNA >1000 copies/mL, 1-2 previous ART
regimens and RNA between 500-1000 copies/mL, or
were on a salvage therapy (>2 previous ART regimens).
GRT is performed in Switzerland in four dedicated
laboratories of the SHCS that use different techniques
[33,34]. One centre uses an in-house test, one uses the
VircoTYPE HIV-1 Assay (Virco Laboratory, Mechelen,
Belgium), and two use the ViroSeq System (Abbott AG,
Baar, Switzerland)
The rPRT system used in Switzerland is based on a
position-precise ligation of patient-derived PR/RT
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sequences into a replication competent background of a
standardized reference HIV-1. As the entire amplified
virus population is retained during DNA plasmid propa-
gation this process represents to the best extent possible
the virus population present in a patient’s blood at the
time of blood draw. The subsequent introduction of the
DNA plasmids into susceptible human reporter cells
initiates a rapid HIV infection. The diagnostic system,
termed deCIPhR/PhenoTecT, allows the reconstituted
HIV to undergo in a time window of four days 3-4
rounds of replication in the presence of each drug sepa-
rately. A first replication round in this system thereby
eliminates any susceptible wild type viruses, while rele-
vant drug resistant variants are amplified during several
cycles. A stably integrated LTR-driven reporter is acti-
vated by HIV Tat, and its expression has been shown to
directly correlate with cellular HIV infection [35]. The
deCIPhR system has been demonstrated to detect resis-
tant variants present at less than 1% in the viral popula-
tion and is able to dissect mixed virus populations. The
short assay duration (6 days) obviates de novo evolution
of resistance in vitro. Details and a comparison with
non-replicative systems have been described earlier
[16-18].
Outcome definition and main predictor
The primary endpoint of the study was virologic
response defined as either HIV-1 RNA viral load <50
copies/mL or a reduction in viral load of ≥1.5 log
copies/mL. Once an individual started the new cART
regimen, any further regimen switches prior to achieving
virological response were defined as a failure unless no
HIV-1 RNA was measured.
Our main predictor was the type of resistance testing
an individual received: GRT alone or GRT plus rPRT.
The following covariates were considered for inclusion
in the analysis to adjust for potential confounding: age
(<40, ≥40 years), gender, current intravenous drug use
(IDU) or participation in a drug maintenance program,
HIV-1 RNA (log10 transformed), nadir CD4 cell count
(square root transformation, per 100 cells per μL), num-
ber of previous cART regimens, cART regimen class,
calendar year and adherence to antiretroviral drugs
(maximum number of self-reported missed cART-doses
in the 4 weeks prior to a cohort visit) [36].
Statistical methods
Baseline characteristics of the eligible population were
summarized overall and by resistance test. We explored
whether rPRT in addition to GRT was associated with
higher rates of virological response. To study the effects
of the type of resistance test on the success of therapy,
multilevel logistic regression analysis was performed.
SHCS centre was included in the model as a random
effect to account for the potential higher correlation in
response among individuals seen at the same centre.
Based on our hypothesis that the benefit of rPRT
would be greatest in those with previous drug failure,
we pre-defined two subgroups for additional analysis:
patients having a resistance test after any treatment fail-
ure and patients having a resistance test after >2 pre-
vious treatment failures.
The association between explanatory variables and
treatment success were assessed by odds ratios (OR)
and 95% confidence intervals (CI); OR above 1 indicate
that a covariate is positively associated with the out-
come. All analyses were done with SAS 9.1 (SAS Insti-
tute, Cary, North Carolina, USA). The manuscript was
written to comply with STROBE (Strengthening the
reporting of observational studies in epidemiology)
guidelines [37].
Results
Baseline characteristics
For the period 2002-2006 we identified 2268 individuals
with a total of 2889 resistance test samples. Of these,
1459 tests from 1204 individuals were excluded. The
reasons for ineligibility were no change of cART follow-
ing resistance testing (49.0%), a change of cART later
than one year following resistance testing (36.1%),
patients being off cART for more than 6 months follow-
ing resistance testing (8.6%), and 6.7% with no available
HIV-1 RNA viral load following resistance testing
(Table 1). The high percentage of the “no change” cate-
gory reflects a combination of those cases where pri-
mary infections were analyzed, or patients after
deliberate therapy interruption, or those with imperfect
therapy compliance. Consequently no treatment adjust-
ment occurred.
Table 1 Exclusion criteria for comparison of GRT versus
GRT + rPRT
All
N (%)
GRT
N (%)
GRT + rPRT
N (%)
Ineligible tests - n
(% of total tests)
1459 1120 339
No change of ART after RT 708 (49.0) 532 (47.5) 176 (51.9)
Change of ART only >1 year
after last RT
526 (36.1) 411 (36.7) 116 (34.2)
Off treatment for >6 months
after RT
126 (8.6) 105(9.4) 21 (6.2)
No RNA during study period* 98 (6.7) 74 (6.6) 25 (7.4)
Other# 1 (0.01) 0.0 1 (0.3)
* The study period is the time from the 1st change of ART after RT until the
earliest of either changing ART due to failure (RNA >400), going off treatment,
or December 31, 2008.
# Participation in a structured treatment interruption trial.
RT = resistance test, GRT = genotype RT, rPRT = replicative phenotype RT,
cART = combined antiretroviral therapy.
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The final study population consisted of 1158 indivi-
duals, with their corresponding resistance tests. Of these
1158 individuals, 937 received GRT and 221 GRT plus
rPRT. The indication for the resistance test was drug
failure (66.5%), testing for transmission of resistant
viruses in naïve patients (28.5%), pregnancy (3.5%), and
unknown (1.5%). There was no relevant difference in
the distribution of the indication for resistance testing
according to the type of resistance test (Table 1).
Table 2 shows the baseline characteristics of the study
population overall and by type of resistance test. The
median age was 41 years (median, inter-quartile range
(IQR) 36-47 years), 69.4% were men, 29.2% had a pre-
vious AIDS diagnosis and 12% of all subjects were cur-
rent IDU or in a drug substitution program at that time.
At baseline (time of resistance testing) HIV-1 RNA was
4.2 log copies/mL (median, IQR: 3.2-4.9 log copies/mL)
and the median CD4 cell count was 261 cells/μL (IQR:
168-387). Of note, 30.2% of the population was drug
naïve and 55.5% currently on therapy with a median of
two previous cART (IQR: 0-6) regimens. Because of dif-
ferences in the local availability of RT across the SHCS
centres, the use of rPRT differed substantially with 2
centres contributing over 80% of rPRT and 2 centres
not performing rPRT at all.
Primary endpoint: virological response after resistance
test
All patients had a minimum of one year of follow-up in
this study. This was considered a sufficiently long period
for achieving virological success on a new regimen even
in situations where patients had been heavily pre-trea-
ted. Following resistance testing 81.4% (n = 763 of 937)
in the GRT group and 85.1% (n = 188 of 221) in the
combined GRT plus rPRT group achieved the primary
endpoint of virological response (either VL <50 copies/
mL or 1.5 log reduction). The type of success achieved
did not vary by type of resistance test with 51.4% of
those with GRT and 49.5% of those with GRT plus
rPRT achieving a VL <50 copies/mL. Success rates for
GRT and GRT plus rPRT in the subset with resistance
testing due to failure were 74.4% and 79.7%, in salvage
patients 69.0% and 77.5%, respectively. The OR in uni-
variable multilevel logistic regression analysis for virolo-
gical response of GRT plus rPRT compared to GRT was
0.85 (95% CI 0.59-1.24) and for the pre-specified sub-
groups of patients with any and >2 previous drug fail-
ures were 1.16 (95% CI 0.73-1.82) and 1.45 (95% CI
1.00-2.09), respectively (Table 3).
For the pre-specified subgroup of patients with >2
previous drug failures this association was highly signifi-
cant in multivariate analysis when adjusting for age,
gender, IDU, baseline HIV-1 RNA, CD4 nadir, number
of previous regimens, class of cART, and missed doses
of cART (OR 1.68, 95% CI 1.31-2.15) (Table 4). The
CD4 nadir, class of cART regimen and self-reported
missed cART doses remained significant predictors of
virological response in this subgroup of patients. As also
shown in table 4 a lower number of patients in the GRT
group remained on NNRTI-containing regimens and, in
contrast, a higher percentage received the newer, see-
mingly more potent PI-based therapies.
The new potent drugs such as darunavir and etravir-
ine were not yet marketed in Switzerland. Nevertheless,
calendar year was considered as a possible confounder
in the model. Yet it was not found to be a relevant vari-
able. When adding it to the multivariable model in
Table 4, the odds ratio for type of resistance test
remained unchanged (OR: 1.68, 95% CI: 1.37-2.04).
Discussion
In this multicentre cohort study of prospectively assessed
HIV-1 drug resistance in patients the addition of rPRT to
GRT as compared to GRT alone showed a trend towards
improved success rates for treatment with increasing
levels of antiretroviral pre-treatment. In the subgroup of
heavily pre-treated patients with multiple drug failures
the addition of rPRT significantly improved virological
outcome with a 70% increased odds for achieving treat-
ment success after adjusting for confounders and SHCS
centre. The clinical benefit of resistance testing must be
critically evaluated in its clinical context. Between 1999
and 2007 resistance declined overall in the SHCS [38].
This decrease was mainly driven by two mechanisms, the
loss to follow-up or death of high-risk patients exposed
to mono- or dual-nucleoside reverse transcriptase inhibi-
tor therapy and the continued enrolment of low risk
patients who were taking cART that contained boosted
protease inhibitors or NNRTI as first-line therapy.
From a virologist’s point of view the add-on benefit of
rPRT is of particular relevance in patients with multiple
drug failure and archived mutations. In patients with
multiple virological drug failure and multiple therapy
changes the genomic complexity of deposited HIV
sequences increases. Growing resistance coincides with
a rise of viral quasispecies [18,39,40]. Although GRT
provides relevant information to clinicians for optimal
drug choices it has important limitations for mixed
virus populations and for the detection of emerging or
residual virus variants. The interpretation of a GRT
results becomes particularly challenging for therapy-
experienced patients where specific mutations have to
be assigned to distinct HIV genomes. Today several
unique rule based algorithms are very well established
e.g. Stanford (HIV drug resistance database, Stanford
university; USA), ANRS (National Agency for
AIDS Research, France), Rega (Institute for Medical
Research and University Hospitals, Belgium), and G2P
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Table 2 Patient characteristics of HIV-infected individuals according to type of resistance test (RT)
All GRT GRT + rPRT
Total tests - n 1158 937 221
Male - % 69.4 68.8 72.0
Age - median [IQR] 41 [36-47] 41 [36-47] 40 [36-47]
Caucasian - % 79.5 79.9 77.8
HIV transmission group - %
Homosexual 39.5 40.7 34.4
Heterosexual 38.0 37.3 41.2
IDU 18.7 18.6 19.5
Other 3.8 3.5 5.0
Current IDU or in drug maintenance program - % 12.0 11.9 12.7
Baseline HIV-1 RNA (copies/mL)†- %
Log RNA - Median [IQR] 4.2 [3.2-4.9] 4.2 [3.2-4.9] 4.2 [3.3-4.9]
= 50 2.6 3.0 0.9
51 - 500 10.6 10.6 10.7
501 - 1000 5.0 5.0 5.1
>1000 81.8 81.4 83.3
Baseline CD4 cell count (109)† - %
Median [IQR] 261 [168-387] 260 [166-387] 266 [180-390]
<200 33.1 33.4 32.1
200 - 349 36.5 36.8 34.9
350 - 499 17.9 17.4 20.1
= 500 12.6 12.5 12.9
Hepatitis C¶ - % 3.2 3.8 0.5
AIDS - % 29.2 29.4 28.5
Number of previous ART regimens
Median [IQR] 2 [0-6] 2 [0-6] 2 [0-5]
Treatment status at time of RT - %
Naïve 30.2 29.5 33.5
Off treatment 14.3 15.5 9.1
Current 55.5 55.1 57.5
ART after RT - %
NNRTI 26.3 24.8 32.6
PI non-boosted 5.9 5.9 5.9
PI boosted 58.8 60.7 50.7
Triple Nucleoside/Other 9.1 8.6 10.9
Maximum missed doses of ART# -%
0 49.9 51.2 45.9
1 15.1 13.5 20.2
2 12.9 13.5 11.0
>2 22.2 21.9 22.9
Missed 2 consecutive doses of ART# - % 19.2 19.1 19.4
SHCS centre at time of RT - %
Basel 12.2 3.0 51.1
Bern 14.8 10.8 31.7
Geneva 19.3 23.8 0
Lausanne 10.0 12.4 0
Lugano 3.1 3.4 1.8
St. Gallen 4.2 2.2 12.2
Zurich 36.5 44.4 3.2
¶ Active/chronic hepatitis C.
† Baseline is the time of RT. Labs closest to before or after the RT.
# In the year prior to RT.
RT = resistance test, GRT = genotypic RT, rPRT = replicative phenotypic RT, ART = antiretroviral therapy, IQR = interquartile range, IDU = intravenous drug use.
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(geno2pheno system, Max-Planck-Institute, Germany).
However, the agreement among these algorithms tends
to decrease in parallel to the growing complexity of viral
mutation patterns [41]. Interpretation and choice of the
optimal regimen becomes particularly difficult for heav-
ily pretreated patients, where the clinical treatment
options become scarce or in situations where drug pres-
sure after longer treatment interruptions is absent.
One intrinsic potential limitation of this study lies in
the fact that the choice of requesting GRT or GRT
+PRT was largely centre-dependent, thereby introducing
a possible centre bias and depending on any centre’s
preference for certain regimens. However by using a
multilevel or hierarchical model, the effect of resistance
testing was estimated after adjusting for the measured
or unmeasured effect of centre.
Our study has several strengths. We used stringent
and very conservative criteria to define the target popu-
lation of this observational cohort study. The cohort
represents an unselected population of HIV-infected
individuals, which is larger than the populations
included in previously published observational studies
and clinical trials. In addition this study includes a rela-
tively large number of females and IDU making it more
representative. We were able to include important vari-
ables in our analysis known to be related to virological
outcome. For example, our data indicate that the study
population included a relatively large group of patients
with adherence problems in comparison to the general
patient population in the SHCS. Roughly one third of
patients had indicated that they had missed more than 2
doses in the previous four weeks and one fifth of
patients stated to have missed more than 2 consecutive
doses. Thus, our findings should be interpreted in the
context of a patient population that poses real chal-
lenges for optimal clinical management and most likely
makes it more difficult to demonstrate an add-on bene-
fit of rPRT to GRT than one would have seen in a clini-
cal trial with a more selected patient population.
High molecular diversity of HIV is a common pro-
blem in long-term treated, highly therapy experienced
patients. In such patients with complex resistances rPRT
is able to assign resistances to several co-existing viruses
Table 3 Multi-level univariable logistic regression models
for virological response in patients with GRT+rPRT
compared to GRT *
n OR (95% CI) p-value
All patients 1158 0.85 (0.59 - 1.24) 0.41
Patients with any failure 770 1.16 (0.73 - 1.82) 0.53
Patients with >2 previous failures 533 1.45 (1.00 - 2.09) 0.05
* Models are hierarchical with follow-up centre included as a random effect.
Virological response is defined as a reduction by ≥1.5 log HIV-1 RNA viral load
or less than 50 copies/mL.
Table 4 Multi-level logistic regression models for virological response in patients with >2 previous failure (n = 533)
with GRT+rPRT compared to GRT *
Model Univariate
OR (95% CI)
Multivariate
OR (95% CI)
Adjusted
p-value
Type of resistance test (GRT+rPRT vs. PRT) 1.45 (1.00 - 2.09) 1.68 (1.31 - 2.15) <0.001
Age (≥40 vs. <40) 1.10 (0.74 - 1.64) 1.22 (0.90 - 1.65) 0.20
Male 0.77 (0.45 - 1.32) 0.80 (0.40 - 1.61) 0.53
Current IDU or in drug maintenance programme 1.27 (0.58 - 2.78) 1.94 (0.97 - 3.90) 0.06
Baseline HIV RNA (log10 copies/mL) 0.83 (0.66 - 1.05) 0.87 (0.64 - 1.18) 0.37
CD4 nadir (square root per 100 cells/μL) 1.66 (1.18 - 2.32) 1.67 (1.16 - 2.41) 0.006
Number of previous ART regimens 0.94 (0.88 - 1.00) 0.95 (0.90 - 1.00) 0.07
ART regimen after RT test
NNRTI Reference Reference
PI non-boosted 0.12 (0.02 - 0.78) 0.13 (0.03 - 0.64) 0.01
PI boosted 0.31 (0.16 - 0.59) 0.43 (0.23 - 0.79) 0.007
Triple nucleoside/Other 0.08 (0.02 - 0.28) 0.08 (0.02 - 0.27) <0.001
Missed doses#
0 Reference Reference
1 0.52 (0.27 - 0.98) 0.42 (0.22 - 0.82) 0.01
2 0.41 (0.16 - 1.05) 0.41 (0.14 - 1.22) 0.11
>2 0.41 (0.29 - 0.58) 0.37 (0.24 - 0.57) <0.001
* Models are hierarchical with follow-up centre included as a random effect. Virological response is defined as HIV-1 RNA viral load <50 copies/mL or reduction
by ≥ 1.5 log.
# Maximum number of missed doses during the study period.
GRT = genotypic RT, rPRT = replicative phenotypic RT, OR = odds ratio, CI = confidence interval, IDU = injecting drug use.
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rather than placing the gene mutations onto one single
virtual virus genome as done by GRT, and thus gives
more conservative estimates of antiretroviral drug resis-
tance. In contrast, GRT in such patients leads to over-
simplification by indicating cross resistance patterns per
viral genome that tend in reality to be more complex.
As a consequence, GRT may in these patients over-
interpret the viral resistance and erroneously indicate to
clinicians and their patients a lower number of remain-
ing treatment options. The higher percentage in the
GRT group of PI containing regimes, paralleled by a
reduction in NNRTI-containing ART combinations sug-
gests two likely reasons: on the one hand a centre effect
for the favoured therapy-scheme, on the other, due to
their low genetic barrier, the prompt stop of NNRTIs
after virological failure. This study did, however, not
assess whether or not this decision was always based on
the formal demonstration of predominant NNRTI-
related resistance mutations.
Previous studies on GRT and PRT have investigated
virological outcome with mixed findings, either resulting
in non-significant gains [19-21] or in only a small bene-
fit [25] and cost savings [22-24] from GRT-guided ther-
apy adjustment. Moreover, several clinical trials have
investigated different types of PRT, but until now a pos-
sible advantage of providing PRT remains unclear. In a
randomized trial of heavily pre-treated patients PRT did
not result in an intention to treat analysis in a greater
proportion of virological suppression when compared to
standard of care. In the as treated analysis a statistically
significant 16% difference of patients with less than 400
c/mL was found [26]. In another randomized trial by
Meynard et al. a less sensitive single-cycle PRT was
used. The combination of PRT with GRT compared to
GRT did not result in a higher rate of HIV-1 suppres-
sion [28]. GRT plus vPRT was compared to GRT in a
large Australian trial but the investigators found at 48
weeks no difference in virological outcome [27]. In one
trial patients with drug failure were randomized either
to access to routine GRT, vPRT, or “no testing”. No dif-
ference in the time to virological failure was found
between groups. However, in the subgroup of patients
with more than four previous failures patients with
vPRT did have significantly prolonged time to treatment
failure [29]. In another randomized controlled trial by
Dunn et al. there was no difference between GRT alone
and GRT plus PRT [30]. Both trial groups worked with
a less sensitive method of PRT compared to the one
used in this study.
Conclusion
Evidence from clinical trials investigating whether GRT,
PRT or the combination of both improve virological
outcome is limited. Subgroup analyses from trials
suggest that PRT may improve clinical outcome in
patients with multiple previous failure. Our findings are
in line with those trials. Our study shows that rPRT,
when added to GRT, may indeed lead to improved viro-
logical outcome, particularly in the population of heavily
pre-treated patients. This is corroborated by the finding
that a therapy status “no treatment at time of testing” is
significantly less frequent for the GRT + rPRT group.
This indicates that GRT + rPRT was more often chosen
in complex therapy situations. As scientific basis: repli-
cative PRT functionally dissects resistant virus popula-
tions and may reveal remaining viable regimens,
particularly in patients with limited options and thereby
increase the chance for virological success. In contrast
GRT tends to place for analysis all mutations on one
viral “consensus” genome.
Our study suggests that a stepwise testing strategy
adding replicative PRT for patients with multiple drug
failure provides benefit for better clinical decision-mak-
ing. Further studies are needed to confirm whether this
strategy translates into improved virological outcome in
patients with limited treatment options.
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